DaVita (NYSE:DVA) Issues FY 2024 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 9.250-10.050 for the period, compared to the consensus EPS estimate of 9.790. The company issued revenue guidance of -. DaVita also updated its FY24 guidance to $9.25-$10.05 EPS.

DaVita Stock Performance

DVA traded up $2.53 on Friday, reaching $142.34. The stock had a trading volume of 419,790 shares, compared to its average volume of 817,015. DaVita has a 12-month low of $76.64 and a 12-month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 15.78. The company has a market cap of $11.67 billion, a P/E ratio of 15.08, a price-to-earnings-growth ratio of 0.82 and a beta of 0.87. The business’s 50-day moving average price is $157.96 and its two-hundred day moving average price is $145.97.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period in the previous year, the firm posted $2.85 EPS. DaVita’s revenue was up 4.6% compared to the same quarter last year. Sell-side analysts forecast that DaVita will post 9.84 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on DVA. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday. Bank of America upped their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Finally, UBS Group boosted their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $161.80.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of DaVita stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 over the last 90 days. 2.00% of the stock is owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.